Journal of Enzyme Inhibition and Medicinal Chemistry · 2023 · 11 citations · 28 references
PharmacyMedicinal ChemistryPharmacologyCancer PharmacologyDrug DesignDrug DiscoveryMolecular DockingVirtual ScreeningCell Line-derived Xenograft ModelsCytotoxicity AssaysHeat Shock Protein InhibitorsInhibitor ScreeningLead Compound DiscoveryLead Compound IdentificationStructure-based ScreeningTherapeutic Target Identification
Heat shock protein 90 (Hsp90) is considered an attractive therapeutic target for cancer treatment due to its high expression in many cancers. In this study, four potent Hsp90 inhibitors (HPs 1–4) were identified using structure-based virtual screening. Among them, HP-4 exhibited the most potent inhibitory effects (IC50 = 17.64 ± 1.45 nM) against the Hsp90 protein, which was about 7.7 times stronger than that of MPC-3100 (a positive inhibitor targeting Hsp90). In vitro cytotoxicity assay suggested that HP-4 could effectively inhibit the proliferation of a series of tumour cells, including HCT-116, HeLa, A549, A2780, DU145, HepG2 and A498. Furthermore, in vivo assay displayed that HP-4 had significant anti-tumour effects on HCT-116 cell-derived xenograft models. These data demonstrate that HP-4 could be a potential lead compound for the further investigation of anti-tumour drugs.
28
A novel Hsp90 inhibitor to disrupt Hsp90/Cdc37 complex against pancreatic cancer cells
Tao Zhang, Adel Hamza, Xianhua Cao et al. · Molecular Cancer Therapeutics · 2008 · 368 citations · Full text
Medicine, Oncology, Pharmacology +9